Citius Pharmaceuticals Inc (Nasdaq: CTXR), a US-based biopharmaceutical company, announced on Tuesday that it has appointed Dr John Laffey to its ARDS Scientific Advisory Board, effective immediately.
Dr Laffey is serving as a professor of Anaesthesia and Intensive Care Medicine at the School of Medicine of the National University of Ireland and a Consultant in Anaesthesia and Intensive Care Medicine at Galway University Hospitals. He holds the position of a director of Clinical Research at Saolta Hospital Group and NUI Galway. He is also a principal investigator at the National Centre for Biomedical Engineering Sciences, and a clinical trials investigator at the HRB Clinical Research Facility at NUI Galway.
Also, Dr Laffey has served as principal investigator or co-principal investigator in multiple clinical trials in the fields of anaesthesia and critical illness.
Myron Holubiak, Citius Pharmaceuticals president and chief executive officer, was quoted as saying: "We are delighted to welcome John to our distinguished ARDS Scientific Advisory Board and look forward to leveraging his deep insights and decades of hands-on experience with ARDS to advance our proprietary i-MSC program."
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer